Brittany Meiling – Page 6 – Endpoints News

about the author

Brittany Meiling

editors@endpointsnews.com

Brittany Meiling on LinkedIn

author articles

Biogen snatches ex-Pfizer exec as new EVP, corporate development; Ionis/Akcea get thumbs up from EMA committee on ...

7 years ago

Ironwood dodges a Denner board seat, but the activist investor still has words of advice

7 years ago

Astellas, FibroGen hit primary endpoint in PhIII; vTv inks PDE4 inhibitor deal with Newsoara

7 years ago

ScPharma's stock droops on 'deficiencies' as FDA tosses back heart failure drug application

7 years ago

Novartis loses a head honcho, with US oncology head Bill Hinshaw exiting for new gig at Axcella

7 years ago

Following ASCO preview flop, Syndax bets on new combo deal with Nektar

7 years ago

Sanofi fires back at Roseanne: 'racism is not a side effect' of Ambien

7 years ago

Zai Lab licenses psoriasis drug from Crescendo; HitGen, Lion raise cash for discovery and development work in Asia

7 years ago

PhRMA's new report counts each cancer drug in the US pipeline, which has now swelled to over 1,000 in the clinic

7 years ago

Racing to grab market share in diabetes, Novo touts its oral semaglutide win over Jardiance in PhIIIa trial

7 years ago

Arcturus' ex-CEO triumphs, ousting board that ousted him

7 years ago

After sinking $300M into SF fund last year, Hong Kong conglomerate launches $100M arm in Shanghai

7 years ago

Kezar and Xeris file for IPOs, joining May's march to the public markets

8 years ago

Magenta Therapeutics unveils plans to raise $100M in IPO weeks after a crossover round

8 years ago

Rockwell's CEO refuses to be fired, kicking up brawl with board that halts the company's stock

8 years ago

Cara hauls in $70M on first leg of global deal, setting up PhIII kidney disease drug for commercial roll out

8 years ago

Versant backs new approach to gamma delta T cells, co-leads Lava's $18.9M round

8 years ago

Sesen's PhIII bladder cancer data send stock south as investors fret over safety

8 years ago

Agile bristles after FDA's third snub, promising a fight for its contraceptive

8 years ago

Forget RNA drugs. Accent gets $40M to develop small molecules that modify RNA instead

8 years ago

FDA approves first non-opioid to treat withdrawal symptoms in adults

8 years ago

Vectalys and FlashCell merge into Flash Therapeutics, loaded with RNA pipeline and manufacturing set-up

8 years ago

Tel Aviv VC fund aMoon gets $250M from Credit Suisse, emerges as top player in Israel

8 years ago

Seattle's Nohla closes $45M to bring novel stem cell treatment for leukemia to late-stage trials

8 years ago

First page Previous page 3 4 567 8 9 Next page Last page